Menkes Disease - Epidemiology Forecast - 2034

Key Highlights

• Menkes disease diagnosed prevalence is expected to rise, driven by advancements in genetic testing, increased awareness, improved survival rates, genetic factors, expanded screening, and environmental influences.
• In 2023, the US accounted for the maximum diagnosed patient share of Menkes disease in the 7MM, i.e., 54%, followed by Japan accounting for around 11% of the total 7MM cases. Among the European countries higher number of cases were in France accounting for about 9% of the total 7MM cases.

The “Menkes Disease - Epidemiology - 2034” report delivers an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Diagnostic Algorithm

Menkes Disease Overview

Menkes disease is a lethal infantile neurodegenerative disorder with X-linked inheritance. It is an inherited X-linked recessive disorder caused by mutations in the ATP7A gene that is responsible for the transport of copper throughout the body. The quality of life (QoL) of Menkes patients deteriorates rapidly through growing severity, symptoms, and outcomes. The newborn may experience seizures, low muscle tone, twisted blood vessels, and many other defects in organs. Also, the mortality rate of patients with Menkes is very high. Seeing their newborn child in such a deadly situation is very painful for parents and families as well. Overall financial and emotional support to families is highly needed. Counseling the family about the ongoing situation and the possibility of occurrence of disease in the family should be done.

Menkes Disease Diagnosis

The diagnosis is the most formidable challenge in Menkes. Test such as biochemical evaluation is a useful tool to estimate the serum copper and ceruloplasmin levels in the patient, which are generally found lower in affected cases. But the levels of copper at birth may overlap with normal, resulting in misdiagnosis. Other most available diagnosis techniques are Neuroimaging, EEG, and others, which are performed after suspected symptoms appear. Diagnosis techniques with high accuracy and precision, such as gene-based tests, are the need of the hour.

Menkes Disease Epidemiology

For the purpose of designing the patient-based model for Inflammatory Myositis (OSA), the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalence of Menkes Disease, in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.

• As per our assessment, in 2023, nearly 177 diagnosed prevalent cases of Menkes Disease were estimated in the 7MM. These cases are anticipated to increase by 2034. The US accounted for the highest cases.
• Among the European countries, France (26%) had the highest diagnosed prevalent population of Menkes Disease, followed by Germany and the UK (24%) in 2023. On the other hand, Spain (11%) had the least diagnosed prevalent population of Menkes Disease in the same year.
• In 2023, Japan accounted for around 19 diagnosed prevalent cases of Menkes disease.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Menkes Disease evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from The Ohio State University College of Medicine, Columbus, Ohio, United States; University of Iowa, Iowa City, Iowa, the US; University Clinic of Marburg, Marburg, Germany; Department of Immunology, Institut Pasteur, France; Department of Pediatrics, Teikyo University School of Medicine, Tokyo, Japan, and others.

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Menkes Disease, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Menkes Disease Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Diagnosed Prevalence of Menkes Disease

Menkes Disease Report Key Strengths

• 11 years Forecast
• The 7MM Coverage
• Menkes Disease Epidemiology Segmentation

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Menkes Disease? What will be the growth opportunities across the 7MM concerning the patient population of Menkes Disease?
• What is the historical and forecasted Menkes Disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis?
• Which country is more prevalent for Menkes Disease and why?
• What factors are affecting the diagnosis of the indication?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Menkes Disease prevalence cases in varying geographies over the coming years.
• A detailed overview of diagnosed prevalence of Menkes Disease.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Menkes Disease Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Menkes Disease cases in 2023?

The highest cases of Menkes Disease was found in the France, among EU4 and the UK, in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Menkes Disease cases in 2023?

The highest cases of Menkes Disease were found in the US, among the 7MM, in 2023.